循环骨形态发生蛋白10作为心力衰竭心房应激与重构的新型标志物
本研究在BIOSTAT-CHF队列2085例慢性心衰患者及苏格兰验证队列1487例患者中,评估循环BMP10作为心房应激与重构生物标志物的潜力,并与NT-proBNP比较。结果显示BMP10与房颤病史及左房直径增大独立相关,且较高BMP10水平可预测2年全因死亡与心衰再住院的复合结局,验证队列结果一致。
要点
- BMP10与房颤病史及左房直径增大独立相关,反映心房应激与重构。
- 较高BMP10水平预测2年全因死亡与心衰再住院复合结局(HR=1.10)。
- BMP10在风险分层和指导心衰治疗方面具有潜在应用价值。
核心结论
- BMP10是反映慢性心衰患者心房应激与重构的新型生物标志物,对不良结局具有额外预测价值。
研究设计与样本
- 在BIOSTAT-CHF队列2085例慢性心衰患者及苏格兰验证队列1487例患者中量化BMP10水平。
- 采用多变量线性回归识别BMP10独立关联因素,并对6369种蛋白进行蛋白质组学分析及基因集富集分析。
- 采用Cox比例风险模型校正既定危险因素,分析BMP10与全因死亡及心衰住院等临床结局的关联。
主要发现
- 在多变量模型(含临床和超声心动图参数)中,对数转换并标准化的BMP10水平与房颤病史显著相关(Sβ=0.419;p<0.001)。
- BMP10与反映心房应激的超声心动图特征如左房直径增大显著相关(Sβ=0.075;p=0.048)。
- 上述关联在NT-proBNP水平的最强关联因素中并未出现。
- 基因集富集分析显示BMP10显著富集于肌肉收缩和细胞外基质组织通路。
- 较高BMP10水平预测2年全因死亡与心衰再住院复合结局(HR=1.10,95%CI=1.02-1.19),验证队列结果可比。
临床怎么用
- BMP10可作为评估慢性心衰患者心房应激与重构的辅助生物标志物。
- BMP10水平有助于增强心衰风险分层并指导治疗干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated the potential of circulating bone morphogenetic protein 10 (BMP10) as a biomarker for atrial stress and remodelling in patients with heart failure (HF), in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP). We also assessed the predictive value of BMP10 for adverse clinical outcomes. METHODS: BMP10 levels were quantified in 2085 chronic HF patients from the European BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) cohort and in 1487 patients from the Scottish validation cohort. Multivariable linear regression identified independent associates of BMP10. Proteomic analysis of 6369 proteins with subsequent gene set enrichment analysis was used to explore biological pathways associated with elevated BMP10. Cox proportional hazards models adjusting for established risk factors were used to associate BMP10 levels with clinical outcomes, including all-cause mortality and HF hospitalisation. RESULTS: In a multivariable model including clinical and echocardiographic parameters, log-transformed and standardised BMP10 levels were significantly associated with a history of atrial fibrillation (Sβ=0.419; p<0.001), and with echocardiographic features reflecting atrial stress, such as increased left atrial diameter (Sβ=0.075; p=0.048). By contrast, these were not among the strongest associates of NT-proBNP levels. Gene set enrichment analysis showed significant overrepresentation in pathways of muscle contraction and extracellular matrix organisation. Higher log-transformed and standardised BMP10 levels predicted a combined outcome of 2-year all-cause mortality and HF rehospitalisation (HR=1.10, 95% CI=1.02-1.19), with the validation cohort yielding comparable results. CONCLUSION: BMP10 emerges as a novel biomarker reflecting atrial stress and remodelling in chronic HF patients. Its additional predictive value for adverse outcomes underscores its potential utility in enhancing risk stratification and guiding therapeutic interventions in HF management.
引用
- Ceelen, Bracun, van Essen, et al. Circulating bone morphogenetic protein 10 as a novel marker of atrial stress and remodelling in heart failure. Heart. 2025. PMID: 39613454. doi:10.1136/heartjnl-2024-324486
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。